Citations

Mayo Clinic

Clear

1936 citation(s) found for "Jacob, J".

132: THE EFFECT OF RED CELL DISTRIBUTION OF WIDTH ON MORTALITY AMONG CARDIAC INTENSIVE CARE UNIT PATIENTS
Rayes, Hamza, Barsness, Gregory W. , Wiley, Brandon M. , Jentzer, Jacob C.

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 49-49

10.1097/01.ccm.0000550889.78881.69 Get It

1188: COLORFUL YET LETHAL: PALYTOXIN-INDUCED LUNG TOXICITY
Ninan, Jacob, Ola, Olatunde

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 570-570

10.1097/01.ccm.0000551932.71678.0d Get It

165: OUTCOMES WITH LOW-DOSE CATECHOLAMINE USE IN UNSELECTED CARDIAC INTENSIVE CARE UNIT PATIENTS
Ternus, Brad, Bennett, Courtney , Jentzer, Jacob C. , Vallabhajosyula, Saraschandra , Wiley, Brandon M. , Kashani, Kianoush

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 64-64

10.1097/01.ccm.0000550920.03677.56 Get It

Cardiac remodelling and haemodynamic characteristics in primary mitral valve regurgitation
Bakkestrøm, Rine , Banke, Ann , Pecini, Redi, Irmukhamedov, Akhmadjon , Nielsen, Søren K. , Andersen, Mads J. , Borlaug, Barry A. , Møller, Jacob Eifer , Borlaug, Barry A , Andersen, Mads Jønsson

Open Heart | December 17, 2018 | Volume: 5 | Issue: 2 | Pages: e000919

10.1136/openhrt-2018-000919 | PMID 30613416 Get It

Objective To assess the association between cardiac morphology and function assessed with cardiac MRI (CMRI) and haemodynamics at rest and during exercise in patients with primary mitral regurgitation (MR). Methods In an observational study, subjects with significant primary MR (N = 46) with effective regurgitant orifice ≥ 0.30 cm2 and left ventricular (LV) ejection fraction > 60% were examined with right heart catheterisation during rest and exercise and CMRI at rest. End-diastolic pressure volume relationship (EDPVR) was assessed using a single beat method using pulmonary capillary wedge pressure (PCWP) and end-diastolic volume. Patients were divided according to normal PCWP at rest (> 12 mm Hg) and with exercise (> 28 mm Hg). Results: Resting regurgitant volume correlated positively with resting PCWP, (r = 0.42, p = 0.002). However, with exercise no association between PCWP and regurgitant volume was seen (r = 0.09, p = 0.55). At rest left atrial (LA) maximal, minimal and volume index at atrial contraction correlated positively with PCWP (r = 0.60; r = 0.55; r = 0.58, all p < 0.001); in contrast none of these correlated with exercise PCWP (all p > 0.2). EDPVR in patients with high PCWP at rest was shifted towards higher volumes for the same pressures. The opposite was seen for patients with high PCWP during exercise where estimated volumes were smaller for the same pressure than patients with normal exercise PCWP. Conclusion In patients with significant MR the degree of regurgitation and LA dilatation is associated with resting PCWP. However, with exercise this association disappears. Estimation of EDPVR suggests lower LV compliance in patients where PCWP is increased with exercise. Clinical trial registration URL: https://clinicaltrials.gov/ct2/show/NCT02961647?term=HEMI&rank=1. ID: NCT02961647
Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Before Left Ventricular Assist Device Surgery
Vallabhajosyula, Saraschandra , Arora, Shilpkumar , Lahewala, Sopan , Kumar, Varun , Shantha, Ghanshyam Palamaner Subash , Stulak, John M., Gulati, Rajiv , Rihal, Charanjit S. , Prasad, Abhiram , Deshmukh, Abhishek , Vallabhajosyula, Saraschandra , Prasad, Abhiram , Jentzer, Jacob C. , Gersh, Bernard J. , Rihal, Charanjit S.

Journal of the American Heart Association | December 16, 2018 | Volume: 7 | Issue: 22 | Pages: No page available

10.1161/jaha.118.010193 | PMID 30571481 Get It

Background There are limited data on the role of temporary mechanical circulatory support ( MCS ) devices for cardiogenic shock before left ventricular assist device ( LVAD ) surgery. This study sought to evaluate the trends of use and outcomes of MCS in cardiogenic shock before LVAD surgery. Methods and Results This was a retrospective cohort study from 2005 to 2014 using the National Inpatient Sample (20% stratified sample of US hospitals). This study identified admissions undergoing LVAD surgery with preoperative cardiogenic shock. Admissions for other cardiac surgery and heart transplant were excluded. Temporary MCS was identified using administrative codes. The primary outcome was hospital mortality and secondary outcomes were hospital costs and lengths of stay in admissions with and without MCS use. In this 10‐year period, 9753 admissions were identified with 40.6% requiring pre‐ LVAD MCS . There was a temporal increase in the frequency of cardiogenic shock associated with an increase in non–intra‐aortic balloon pump MCS devices. The cohort receiving MCS had greater in‐hospital myocardial infarction, ventricular arrhythmias, and use of coronary angiography. On multivariable analysis, older age, myocardial infarction, and need for MCS devices were independently predictive of higher in‐hospital mortality. In 696 propensity‐matched pairs, use of MCS was predictive of higher in‐hospital mortality (odds ratio 1.4 [95% confidence interval 1.1–1.6]; P =0.02) and higher hospital costs, but similar lengths of stay. Conclusions In patients with cardiogenic shock bridged to LVAD therapy, there was a steady increase in preoperative MCS use. Use of MCS identified patients at higher risk for in‐hospital mortality and greater resource utilization.
Seasonal variability is not observed in the rates of high anti‐A and anti‐B titers in plasma, apheresis platelet, and whole blood units tested by different methods
Harm, Sarah K., Yazer, Mark H. , Jacob, Eapen K., Mair, David , Raval, Jay S. , Shaz, Beth H. , Ziman, Alyssa , Collaborative, on behalf of the Biomedical Excellence for Safer Transfusion (BEST), Dunbar, Nancy M , Shaz, Beth H , Ziman, Alyssa , Raval, Jay S , Bub, Carolina Bonet , Cohn, Claudia S. , Kutner, José Mauro , Dunbar, Nancy M. , Collaborative, on behalf of the Biomedical Excellence for Safer Transfusion (BEST)

Transfusion | December 12, 2018 | Volume: 59 | Issue: 2 | Pages: 762-767

10.1111/trf.15083 | PMID 30548267 Get It

BACKGROUNDABO‐incompatible platelet transfusions are common, and transfusions with ABO‐incompatible plasma are increasing with the use of group A plasma and group O whole blood (WB) in emergencies. Many centers screen blood products for anti‐A and/or anti‐B titers to help prevent hemolysis from ABO‐incompatible transfusions, yet titer methods and definition of high titers are not standardized.STUDY DESIGN AND METHODSThis international multicenter study collected data on anti‐A and anti‐B titer practices for plasma, apheresis platelet (AP), and WB units from January 2015 through December 2017 to determine the prevalence of high‐titer units using local definitions.RESULTSA total of 87,701 plasma, AP and WB units were screened for high‐titer anti‐A and/or anti‐B. High‐titer detection rates for group A plasma ranged 0%–13.6%; group A AP 2.7%–9.3%; group O AP 2.3%–65.7%; and group O WB 6.4%–20.7%. At the one center that collected group B AP, the high‐titer rate was 10.9%. High‐titer rates varied from month to month, as well as between years for a given month. There was no clear pattern of when high‐titer units were donated.CONCLUSIONThe prevalence of high‐titer plasma, AP, and WB units varies by titer method and local definition of high titer. Even at the lowest titer threshold of 50, a significant proportion of units had a high‐titer antibody, although the clinical relevance of this finding needs further investigation.
Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop
Schmader, Kenneth E. , Abernethy, Darrell R., Gray, Shelly L. , Dunbar‐Jacob, Jacqueline , Holmes, Holly M. , Murray, Michael D. , Roberts, Robert , Peterson, Josh F. , Lindeman, David , Downey, Laura , Rich, Michael W. , Joyner, Michael, Peterson, Josh F , Schwartz, Janice B. , Hanlon, Joseph T. , Abernethy, Darrell R., Joyner, Michael J. , Tai‐Seale, Ming

Journal of the American Geriatrics Society | December 7, 2018 | Volume: 67 | Issue: 2 | Pages: 371-380

10.1111/jgs.15634 | PMID 30536694 Get It

OBJECTIVES To identify the top priority areas for research to optimize pharmacotherapy in older adults with cardiovascular disease (CVD). DESIGN Consensus meeting. SETTING Multidisciplinary workshop supported by the National Institute on Aging, the American College of Cardiology, and the American Geriatrics Society, February 6–7, 2017. PARTICIPANTS Leaders in the Cardiology and Geriatrics communities, (officers in professional societies, journal editors, clinical trialists, Division chiefs), representatives from the NIA; National Heart, Lung, and Blood Institute; Food and Drug Administration; Centers for Medicare and Medicaid Services, Alliance for Academic Internal Medicine, Patient‐Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, pharmaceutical industry, and trainees and early career faculty with interests in geriatric cardiology. MEASUREMENTS Summary of workshop proceedings and recommendations. RESULTS To better align older adults’ healthcare preferences with their care, research is needed to improve skills in patient engagement and communication. Similarly, to coordinate and meet the needs of older adults with multiple comorbidities encountering multiple healthcare providers and systems, systems and disciplines must be integrated. The lack of data from efficacy trials of CVD medications relevant to the majority of older adults creates uncertainty in determining the risks and benefits of many CVD therapies; thus, developing evidence‐based guidelines for older adults with CVD is a top research priority. Polypharmacy and medication nonadherence lead to poor outcomes in older people, making research on appropriate prescribing and deprescribing to reduce polypharmacy and methods to improve adherence to beneficial therapies a priority. CONCLUSION The needs and circumstances of older adults with CVD differ from those that the current medical system has been designed to meet. Optimizing pharmacotherapy in older adults will require new data from traditional and pragmatic research to determine optimal CVD therapy, reduce polypharmacy, increase adherence, and meet person‐centered goals. Better integration of the multiple systems and disciplines involved in the care of older adults will be essential to implement and disseminate best practices. J Am Geriatr Soc 67:371–380, 2019.
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1
Block, Matthew S. , Nevala, Wendy K. , Pang, Yuan‐Ping , Allred, Jacob B., Strand, Carrie , Pang, Yuan-Ping , Markovic, Svetomir N.

Melanoma Research | December 5, 2018 | Volume: 29 | Issue: 4 | Pages: 420-427

10.1097/cmr.0000000000000556 | PMID 30520800 Get It

A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote epitope spreading) and/or resiquimod (to activate antigen-presenting cells). HLA-A2-positive patients with resected stage II, III, and IV melanoma were assigned to treatment on one of three schedules. All patients received three subcutaneous doses of the peptide MART-1a mixed with Montanide. In addition, patients on schedule 1 received the xenoantigen peptide Gag267–274, patients on schedule 2 received topical resiquimod, and patients on schedule 3 received both Gag267–274 and resiquimod. Blood samples were tested for the frequency of antigen-specific T cells by tetramer assay, as well as immune cell subtypes and plasma cytokine levels. Patients enrolled from October 2012 to December 2014, with 10 patients enrolling to each schedule. The most common adverse events were injection site reaction (26 patients) and fatigue (15 patients). Tetramer analysis revealed antigen-specific responses (defined as doubling of MART-1a-specific T cells from pretreatment to post-treatment) in 20, 60, and 40% of patients treated on schedules 1, 2, and 3, respectively. Vaccine treatment consisting of MART-1a peptide, Gag267–274, Montanide, and topical resiquimod was well-tolerated. The addition of the Gag267–274 xenoantigen was not associated with an increase in the response to MART-1a, whereas use of topical resiquimod was associated with a higher frequency of MART-1a-specific T-cell responses that did not meet statistical significance.
Hyperoxia-Induced Cellular Senescence in Fetal Airway Smooth Muscle Cells
Parikh, Pavan , Britt, Rodney D. , Manlove, L., Wicher, Sarah A. , Roesler, A.M., Ravix, Jovanka, Teske, Jacob J. , Kirkland, James L. , Tschumperlin, Daniel J. , Prakash, Y. S. , LeBrasseur, Nathan, Prakash, Y S , Teske, Jacob J , Thompson, Michael A. , Sieck, Gary C. , LeBrasseur, Nathan K. , Pabelick, Christina M.

American Journal of Respiratory Cell and Molecular Biology | December 3, 2018 | Volume: 61 | Issue: 1 | Pages: 51-60

10.1165/rcmb.2018-0176oc | PMID 30508396 Get It

Abstract Supplemental O2 (hyperoxia; 30–90% O2) is a necessary intervention for premature infants, but it contributes to development of neonatal and pediatric asthma, necessitating better understanding of contributory mechanisms in hyperoxia-induced changes to airway structure and function. In adults, environmental stressors promote formation of senescent cells that secrete factors (senescence-associated secretory phenotype), which can be inflammatory and have paracrine effects that enhance chronic lung diseases. Hyperoxia-induced changes in airway structure and function are mediated in part by effects on airway smooth muscle (ASM). In the present study, using human fetal ASM cells as a model of prematurity, we ascertained the effects of clinically relevant moderate hyperoxia (40% O2) on cellular senescence. Fetal ASM exposed to 40% O2 for 7 days exhibited elevated concentrations of senescence-associated markers, including β-galactosidase; cell cycle checkpoint proteins p16, p21, and p-p53; and the DNA damage marker p-γH2A.X (phosphorylated γ-histone family member X). The combination of dasatinib and quercetin, compounds known to eliminate senescent cells (senolytics), reduced the number of hyperoxia-exposed β-galactosidase–, p21-, p16-, and p-γH2A.X–positive ASM cells. The senescence-associated secretory phenotype profile of hyperoxia-exposed cells included both profibrotic and proinflammatory mediators. Naive ASM exposed to media from hyperoxia-exposed senescent cells exhibited increased collagen and fibronectin and higher contractility. Our data show that induction of cellular senescence by hyperoxia leads to secretion of inflammatory factors and has a functional effect on naive ASM. Cellular senescence in the airway may thus contribute to pediatric airway disease in the context of sequelae of preterm birth.
Home Health Care Availability and Discharge Delays in Children With Medical Complexity
Maynard, Roy, Cady, Rhonda , Jacob, Abraham, Ouellette, Yves , Podgorski, Heather, Schiltz, Brenda , Schwantes, Scott, Wheeler, William , Christensen, Eric , Jacob, Abraham

Pediatrics | December 3, 2018 | Volume: 143 | Issue: 1 | Pages: No page available

10.1542/peds.2018-1951 | PMID 30509929 Get It

BACKGROUND: An increasing proportion of pediatric hospital days are attributed to technology-dependent children. The impact that a pediatric home care nursing (HCN) shortage has on increasing length of hospital stay and readmissions in this population is not well documented. METHODS: We conducted a 12-month multisite prospective study of children with medical complexity discharging with home health. We studied the following 2 cohorts: new patients discharging for the first time to home nursing and existing patients discharging from the hospital to previously established home nursing. A modified delay tool was used to categorize causes, delayed discharge (DD) days, and unplanned 90-day readmissions. RESULTS: DD occurred in 68.5% of 54 new patients and 9.2% of 131 existing patients. Lack of HCN was the most frequent cause of DD, increasing costs and directly accounting for an average length of stay increase of 53.9 days (range: 4–204) and 35.7 days (3–63) for new and existing patients, respectively. Of 1582 DDs, 1454 (91.9%) were directly attributed to lack of HCN availability. DD was associated with younger age and tracheostomy. Unplanned 90-day readmissions were due to medical setbacks (96.7% of cases) and occurred in 53.7% and 45.0% of new and existing patients, respectively. CONCLUSIONS: DD and related costs are primarily associated with shortage of HCN and predominantly affect patients new to HCN. Medical setbacks are the most common causes of unplanned 90-day readmissions. Increasing the availability of home care nurses or postacute care facilities could reduce costly hospital length of stay.